Wenyan W. is a drug development leader with over 20 years of experience within multinational corporations and biotech companies. Wenyan has spent more than 15 years focused on clinical development, achieving successful IND and NDA filings through leadership in various clinical programs, including a role as Vice President at Centessa Pharmaceuticals, overseeing the SerpinPC hemophilia program. At Novartis, Wenyan directed global clinical trials, notably the PARAGON-HFpEF outcome trial and was instrumental in the global submission of Entresto. Currently, Wenyan serves as Vice President of Clinical Development at 89bio and is a Postdoctoral Research Fellow at Columbia University, while holding advanced degrees in biochemistry from Sichuan University and Iowa State University.
This person is not in any teams
This person is not in any offices